Decree of the Ministry of Health No. 291 / 1998 Coll.
Decree of the Ministry of Health amending Decree of the Ministry of Health No. 57 / 1997 Coll., which provides for medicinal products fully covered by health insurance and the amount of payments of individual active substances, as amended
Valid
Order
Effective from 01.01.1999
Text versions:
01.01.1999
10.12.1998
291
DECLARATION
Ministry of Health
of 27 November 1998
amending Decree of the Ministry of Health No 57 / 1997 Coll., laying down the medicinal products fully covered by the health insurance and the amount of the payments of the individual active substances, as amended
According to § 15 (5) of Act No. 48 / 1997 Coll., on Public Health Insurance and on the amendment and addition of certain related laws, the Ministry of Health provides for:
Decree No 57 / 1997 Coll., laying down the medicinal products fully covered by the health insurance and the amount of the payments of individual active substances, as amended by Regulations No 109 / 1997 Coll., No 131 / 1997 Coll., No 220 / 1997 Coll., No 317 / 1997 Coll., No 72 / 1998 Coll., No 133 / 1998 Coll. and No 209 / 1998 Coll., Annex Section B is amended as follows:
1. row 45.1 reads as follows:
| „45.1 | A10AA | insuliny (rozpustné humánní, 100 U/ml, cartridge) | parent. | 40 | U | 26,80 | L/DIA“. |
2. after row 45.1, entries 76316, 75419, 76061, 92608, 90979, 96713 and 96732 are deleted:
| „76316 | VELOSULIN HM 100 UT/MLI | inj 1x10 ml/1 ku | NOO | DK |
| 75419 | INSUMAN HOECHST RAPID OPTIPEN | inj 5x3ml/300ut | HOE | A |
| 76061 | ACTRAPID HM PENFILL | 5x3 ml/300ut | NOO | DK |
| 92608 | HUMULIN R CARTRIDGE | 5x3 ml/300ut | LIL | F |
| 90979 | ACTRAPID HM PENFILL | 5x1,5 ml/150ut | NOO | DK |
| 96713 | HUMULIN N (NPH) CARTRIDGE | 5x1,5 ml/150ut | LIL | F |
| 96732 | HUMULIN R CARTRIDGE | 5x1,5 ml/150ut | LIL | F“. |
3. Row 45.3 reads:
| „45.3 | A10AA | insuliny (rozpustné lisylinsuliny) | parent. | 40 | U | 31,45 | L/DIA“. |
4. After row 45.3, entry 89133 is deleted:
| „89133 | HUMALOG 40 IU | inj 1x10m1/400ut | LIL | F“. |
5. Row 45.4 reads:
| „45.4 | A10AA | insuliny (rozpustné lisylmsuhny, 100 U/ml cartridge) | parent | 40 | U | 33,90 | L/DIA |
6. Row 47.1 reads:
| „47.1 | A10AA | insuliny (suspenzní humánní, 100 U/ml, cartridge) | parent. | 40 | U | 26.8 | L/DIA“. |
7. after row 47.1, entries 75420,75421, 75422, 75423, 92604,92605, 92607, 99400, 99401, 61169, 61168, 99408, 61167, 61166, 91162, 61163, 99407, 61164 and 61165 are deleted:
| „75420 | INSUMAN HOECHST BASAL OPTIPEN | inj 5x3 ml/300 ut | HOE | A |
| 75421 | INSUMAN HOECHST KOMB T15 OPTIPEN | inj 5x3 ml/300 ut | HOE | A |
| 75422 | INSUMAN HOECHST KOMB T25 OPTIPEN | inj 5x3 ml/300 ut | HOE | A |
| 75423 | INSUMAN HOECHST KOMB T50 OPTIPEN | inj 5x3 ml/300 ut | HOE | A |
| 92604 | HUMULIN M2 (20/80) CARTRIDGE | inj 5x3 ml/300 ut | LIL | F |
| 92605 | HUMULIN M3 (30!70) CARTRIDGE | inj 5x3 ml/300 ut | LIL | F |
| 92607 | HUMULIN N (NPH) CARTRIDGE | inj 5x3 ml/300 ut | LIL | F |
| 99400 | INSULATARD HM PENFILL | inj. 5x1,5ml/150ut | NOO | DK |
| 99401 | INSULATARD HM PENFILL | inj. 5x3ml/300ut | NOO | DK |
| 61169 | MIXTARD 10 PENFILL | 5x3 ml/300ut | NOO | DK |
| 61168 | MIXTARD 20 PENFILL | 5x3 ml/300ut | NOO | DK |
| 99408 | MIXTARD 30 HM PENFILL | 5x3 ml/300ut | NOO | DK |
| 61167 | MIXTARD 40 HM PENFILL | 5x3 ml/300ut | NOO | DK |
| 61166 | MIXTARD 50 HM PENFILL | 5x3 ml/300ut | NOO | DK |
| 91162 | MIXTARD 10 PENFIL | 5x1.5ml/150ut | NOO | DK |
| 61163 | MIXTARD 20 PENFILL | 5x1.5/150ut | NOO | DK |
| 99407 | MIXTARD 30 HM PENFILL | 5x1.5/150ut | NOO | DK |
| 61164 | MIXTARD 40 PENFILL | 5x1.5/150ut | NOO | DK |
| 61165 | MIXTARD 50 PENFILL | 5x1.5l150ut | NOO | DK“. |
8. Row 49.1 reads:
| „49.1 | A10BA02 | metformin | p.o. | 2 | GM | 8,5 | “. |
9. Line 50.11 reads:
| „50.1 1 | A10BB09 | gliklazid | p.o. | 0,16 | GM | 8,05 | “. |
10. Line 63.3 reads:
| „63.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | p.o. | 3 | GM | 2,55 | “. |
11. the following row 69.3 is inserted after row 69.2:
| „69.3 | A16AA02 | ademetionin | parent. | 0,5 | GM | 109,50 | Z“ |
12. the following row 69.4 is inserted after row 69.3:
| „69.4 | A16AA02 | ademetionin | p.o. | 1 | GM | 61,20 | Z“. |
13. Line 74.1 reads:
| „74.1 | B01AC05 | ticlopidin | p.o. | 0,5 | GM | 52,- | P“. |
14. the following row 74.6 is inserted after row 74.5:
| „74.6 | B01AC | lysin acetylosalicylát (do 160 mg ekvivalentu kys. acetylosalicylové včetně v jedné dávce) | p.o. | 1 | DF | 0,70 | “. |
15. the following row 86.9 is inserted after row 86.8:
| „86.9 | B03AB | soli trojmocného železa (tekuté lékové formy) | p.o. | 0,1 | GM | 5,60 | “. |
16. Row 136.2 reads:
| „136..2 | C03EA01 | hydrochlorothiazid a kalium šetřící látky | p.o. | 0,5 | DF | 0,55 | “. |
17. after row 136.2, entries 83716, 55924, 70515, 60194 and 60196 are deleted:
| „83716 | AMILORID HCT AL | tbl 20 | APA | D |
| 55924 | AMILORIO HCT AL | tbl 30 | APA | D |
| 70515 | APO-AMILZIDE 5/50MG | tbl 100x5mg/50mg | APT | CND |
| 60194 | AQUARETIC | tb 30 | AZU | D |
| 60196 | AQUARETIC | tb 100 | AZU | D“. |
18. Row 169.4 reads:
| „169.4 | C10AB05 | fenofibrát | p.o. | 0,3 | GM | 8,60 | “. |
19. the following row 169.8 is inserted after row 169.7:
| „169.8 | C10AB05 | fenofibrát (retardované lékové formy) | p.o. | 0,3 | GM | 15,20 | “. |
20. Line 181.4 reads:
| „181.4 | D06AX | neomycin/bacitracin (zásyp nad 2 do 5 g v jednom balení včetně | lok. | 1 | GM | 7,05 | “. |
21. the following row 181.10 is inserted after row 181.9:
| „181.10 | DO6AX | neomyciNbacitracin (zásyp nad 5 g v jednom balení) | lok. | 1 | GM | 2,40 | “. |
22. Line 192.11 reads:
| „192.11 | D10AF52 | erythromycin v kombinaci | lok. | 1 | ML | 3,- | “. |
23. the following row 195.5 is inserted after row 195.4:
| „195.5 | G01AA | neomycin/polymyxin/nystatin | vag. | 1 | DF | 11,15 | “. |
24. Line 197.9 reads:
| „197.9 | G01AX12 | ciklopirox (vaginální krém) | vag. | 1 | GM | 3,60 | “. |
25. after row 197.9, entry 76153 is deleted:
| „76153 | BATRAFEN | crm vag 40gm+6xapl. | HBS | SK“. |
26. the following rows 197.12 and 197.13 are inserted after row 197.11:
| „197.12 | G01AX12 | ciclopirox (vaginátní roztok) | vag. | 1 | DF | 18,- | |
| 197,13 | G01AX12 | ciclopirox (vaginální čípky) | vag. | 1 | DF | 18,- | “. |
27. Line 215.2 reads:
| „215.2 | G03GA04 | urofollitrofin | parent. | 75 | U | 410,- | Z“. |
28. Lines 238.1 and 238.2 read:
| „238.1 | H05BA01 | kalcitonin (lososí, do 100 U včetně v jedné dávce) | inhal. | 200 | U | 214,30 | L/INT,GYN,ORT, END |
| 238,2 | H05BA01 | kalcitonin (lososí, nad 100 U v jedné dávce) | inhal. | 200 | U | 118,35 | L/INT,GYN,ORT, END“. |
29. Row 239.1 reads:
| „239.1 | H05BA01 | kalcitonin (lososí) | parent. | 100 | U | 128,25 | L/INT,GYN,ORT, END“. |
30. after row 239.1, row 239.2 is deleted:
| „239.2 | HOSBA01 | kalcitonin (lososí, nad 50 U v jedné ampuli) | parent. | 100 | U | 161,- | L/INT,GYN,ORT, END“. |
31. rows 262.1 and 262.2 read:
| „262.1 | J01FF01 | klindamycin (pevné lékové formy) | p.o. | 1,2 | GM | 69,70 | |
| 262.2 | J01FF01 | klindamycin (tekuté lékové formy) | p.o. | 11,2 | GM | 164,30 | “. |
32. Lines 263.1 and 263.2 read:
| „263 1 | J01FF01 | klindamycin (do 0,3 GM včetně v jedné ampuli) | parent. | 1,8 | GM | 704,10 | U |
| 263.2 | J01FF01 | klindamycin (nad 0,3 GM v jedné ampuli) | parent. | 1,8 | GM | 660,60 | U“. |
33. Line 266.8 reads:
| „266.8 | J01MA09 | sparfloxacin | p.o. | 0,2 | GM | 30,- | “. |
34. the following row 266.9 is inserted after row 266.8:
| „266.9 | J01MA | trovafloxacin | p.o. | 0,2 | GM | 30,- | “. |
35. the following row 267.5 is inserted after row 267.4:
| „267.5 | JO1MA | trovafloxacin | parent. | 0,2 | GM | 224,- | U/ATB“. |
36. In the text after row 274, in point (b), the words "Based on culture examination 'are replaced by the words" Based on culture or microscopic examination, in the case of severe forms of nail mycosis subject to the approval of a revision physician'.
37. In the text after row 281, in the sentence beginning with "Treatment of antiretroviral medicinal products (zidovudine, didanosine, zalcitabine, saquinavir, ritonavir and indavir) ', the words" and stavudine' are inserted after the word "indavir '.
38. the following row 281.14 is inserted after row 281.13:
| „281.14 | J05AX04 | stavudin | p.o. | 80 | MG | 309,- | P“. |
39. Line 284.1 reads:
| „284.1 | J068A01 | imunoglobuliny, norm. Iidské, k extravasální aplikaci | parent. | 1 | DF | 58,- | O“. |
40. After row 284.1, entry 01263 is deleted:
| „01263 | NORGA I.M.SEVAC | inj 10x1.9ml | SEV | CZ“. |
41. Line 323.2 reads:
| „323.2 | L03AA02 | filgrastim | parent. | 1 | MG | 12538,- | X“. |
42. Line 323.4 reads:
| „323.4 | L03AA10 | lenograstim | parent. | 1 | MG | 14302,50 | X“. |
43. the following row 323.9 is inserted after row 323.8:
| „323.9 | L03AA11 | interferon beta 1 a (výhradně pro intramuskulární užití) | parent. | 1 | DF | 9390,- | X“. |
44. Line 351.6 reads:
| „351.6 | M03BX04 | tolperison | p.o. | 200 | MG | 3,- | “. |
45. Line 351.7 reads:
| „351.7 | M03BX04 | tolperison | parent. | 200 | MG | 10,40 | “. |
46. the following rows 351.8 and 351.9 are inserted after row 351.7:
| „351.8 | M038X05 | thiocolchicosid | p.o. | 12 | MG | 10,20 | |
| 351.9 | M038X05 | thiocolchicosid | parent. | 12 | MG | 40,- | “. |
47. Line 356.2 reads:
| „356.2 | M05BA04 | kyselina alendronová | p.o. | 10 | MG | 52,20 | P“. |
48. the following rows 368.7 and 368.8 are inserted after row 368.6:
| „368.7 | N02AA01 | morfin (tekuté lékové formy, do 200 mg včetně v jednom balení) | p.o. | 0,1 | GM | 40,- | |
| 368.8 | N02AA01 | morfin (tekuté lékové formy, nad 200 mg v jednom balení) | p.o. | 0,1 | GM | 18,- | “. |
49. Row 402.3 reads:
| „402.3 | N04BC02 | pergolidi mesilas (do 0,05 mg včetně v jedné tabletě) | p.o. | 3 | MG | 181,- | X“. |
50. Row 402.5 reads:
| „402.5 | N04BC05 | pramipexol | p.o. | 1,5 | MG | 80,- | X“. |
51. the following rows 402.6 and 402.7 are inserted after row 402.5:
| „402.6 | N04BC02 | pergolidi mesilas (nad 0,05 mg do 0,25 mg včetně v jedné tabletě) | p.o. | 3 | MG | 149,- | X |
| 402.7 | N04BC02 | pergolidi mesilas (nad 0,25 mg v jedné tabletě) | p.o. | 3 | MG | 136,- | X“. |
52. Line 439.2 reads:
| „439.2 | P01BA02 | hydroxychlorochin | p.o. | 0,4 | GM | 18,55 | P“. |
53. the following sentence is inserted after row 451:
"Treatment with inhaled salmeterol and formoterol is indicated by an allergist and a pneumologist in persistent asthma where asthma is not fully controlled when the corticosteroid is administered via the inhalation route and by the patient's good cooperation."
54. Lines 451.11 to 451.15 read:
| „451.11 | R03AC12 | salmeterol (lékové formy aerosolu) | inhal. | 0,1 | MG | 21,10 | P |
| 451.12 | R03AC12 | salmeterol (lékové formy prášku k inhalaci) do 0,025 miligramů včetně v jedné dávce | inhal. | 0,1 | MG | 35,- | P |
| 451.13 | R03AC12 | salmeterol (lékové formy prášku k inhahaci) nad 0,025 miligramů v jedné dávce | inhal. | 0,1 | MG | 32,- | P |
| 451.14 | R03AC13 | formoterol (lékové formy prášku k inhalaci) do 4,5 RG včetně v jedné dávce | inhal. | 24 | RG | 35,- | P |
| 451.15 | R03AC13 | formoterol (lékové formy prášku k inhalaci) nad 4,5 RG v jedné dávce | inhal. | 24 | RG | 32,- | P“. |
55. the following row 463.10 is inserted after row 463.9:
| „463.10 | R05CB15 | erdostein | p.o. | 450 | MG | 8,50 | “. |
56. the following row 464.5 is inserted after row 464.4:
| „464.5 | R05CB15 | erdostein | inhal. | 450 | MG | 8,50 | “. |
57. the following rows 482.11 and 482.12 are inserted after row 482.10:
| „482.11 | S01CA05 | betamethason a antiinfektiva (lékové formy očních mastí) | lok. | 1 | GM | 20,- | L/OPH |
| 482.12 | S01CA05 | betamethason a antiinfektiva (lékové formy očních kapek) | lok. | 1 | ML | 20,- | L/OPH“. |
58. the following row 506.11 is inserted after row 506.10:
| „506.11 | V04CX | urea | p.o. | 1 | DF | 1500,- | Z“. |
This Decree shall take effect on 1 January 1999.
Minister:
Dr. David, CSc.
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Decree of the Ministry of Health No. 291 / 1998 Coll., amending Decree of the Ministry of Health No. 57 / 1997 Coll., which provides for medicinal products fully covered by health insurance and the amount of payments of individual active substances, as amended |
|---|---|
| Regulation Type | Order |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 10.12.1998 |
|---|---|
| Effective from | 01.01.1999 |
| Effective until | - |
| Status | Valid |
The regulation text is for informational purposes only.
Comments 0